Brainstem manifestations in neuromyelitis optica: A multicenter study of 258 patients

Multiple Sclerosis Journal

Volumn 20, Issue 7, 2014, Pages 843-847

  Kremer, Laurent ^a   Mealy, M ^b   Jacob, A ^c   Nakashima, I ^d   Cabre, P ^e   Bigi, S ^f   Paul, F ^g   Jarius, S ^h   Aktas, O ⁱ   Elsone, L ^c   Mutch, K ^c   Levy, M ^b   Takai, Y ^d   Collongues, N ^a   Banwell, B ^f   Fujihara, K ^d   De Seze, J ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d TOHOKU UNIVERSITY   (Japan)

^e Department of Neurology Centre Hospitalier la Meynard   (France)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anti aquaporin 4 antibodies; Brainstem; Demyelinating diseases; Epidemiology; Ethnicity; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; AUTOANTIBODY; BIOLOGICAL MARKER;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ATAXIA; BRAIN DISEASE; BRAIN STEM; BRAINSTEM MANIFESTATION; COHORT ANALYSIS; CRANIAL NEUROPATHY; DIPLOPIA; DISEASE DURATION; DYSARTHRIA; DYSPHAGIA; EYE MOVEMENT DISORDER; FACIAL NERVE PARALYSIS; FEMALE; HEARING IMPAIRMENT; HICCUP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOOPTIC NEUROPATHY; PROSPECTIVE STUDY; PRURITUS; SEROLOGY; TRIGEMINUS NEURALGIA; VERTIGO; VESTIBULAR ATAXIA; VESTIBULAR DISORDER; VOMITING; BLOOD; CLINICAL TRIAL; DIAGNOSTIC IMAGING; ETHNOLOGY; EUROPE; IMMUNOLOGY; JAPAN; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; AUTOIMMUNE DISEASE; CAUCASIAN; CONTROLLED STUDY; DEMOGRAPHY; OPTIC NERVE; SPINAL CORD;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; BIOMARKERS; BRAIN STEM; EUROPE; FEMALE; HICCUP; HUMANS; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; NEUROMYELITIS OPTICA; NORTH AMERICA; PREVALENCE; RISK FACTORS; SEROLOGIC TESTS; VOMITING;

EID: 84902187911     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513507822     Document Type: Article

References (32)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114 (Pubitemid 29442132)
2. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489 (Pubitemid 43958540)
3. Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatr 2012; 84: 922-930
4. Wingerchuk DM and Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003; 60: 848-853 (Pubitemid 36297372)
5. Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 2012; 3: 58-73
6. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2: 117-127 (Pubitemid 37443332)
7. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001; 56: 507-514 (Pubitemid 32172877)
8. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135: 1834-1849
9. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005; 65: 1479-1482 (Pubitemid 41552787)
10. Chalumeau-Lemoine L, Chretien F, Gaëlle Si Larbi A, et al. Devic disease with brainstem lesions. Arch Neurol 2006; 63: 591-593
11. Hage R Jr, Merle H, Jeannin S, et al. Ocular oscillations in the neuromyelitis optica spectrum. J Neuroophthalmol 2011; 31: 255-259
12. Wang K-C, Lee C-L, Chen S-Y, et al. Prominent brainstem symptoms/signs in patients with neuromyelitis optica in a Taiwanese population. J Clin Neurosci 2011; 18: 1197-1200
13. Popescu BFG, Lennon, VA Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications. Neurology 2011; 76: 1229-1237
14. Cabre P, Gonzalez-Quevedo A, Lannuzel A, et al. [Descriptive epidemiology of neuromyelitis optica in the Caribbean basin]. Rev Neurol (Paris) 2009; 165: 676-683
15. Cabre P, Signate A, Olindo S, et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005; 128: 2899-2910 (Pubitemid 41746643)
16. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, et al. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009; 256: 35-44
17. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012; 9: 14-31
18. Iorio R, Lucchinetti CF, Lennon VA, et al. Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol 2012; 11: 240-245
19. Patel V, Griffith NC, Blackwood E, et al. Spectrum disorder of neuromyelitis optica in a patient presenting with intractable vomiting and hiccups, transverse myelitis and acute encephalopathy. J Clin Neurosci 2012; 19: 1576-1578
20. Bourre B, Lefaucheur R, Ozkul O, et al. [Intractable vomiting as first manifestation of neuromyelitis Optica.]. Rev Neurol (Paris) 2012; 169: 90-91
21. Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010; 68: 757-761
22. Riphagen J, Modderman P and Verrips A. Hiccups, nausea, and vomiting: Water channels under attack! Lancet 2010; 375: 954
23. Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: A herald of acute exacerbations. J Neurol Neurosurg Psychiatr 2008; 79: 1075-1078
24. Yavuz H and Kiresi D. Unusual manifestations of pediatric neuromyelitis optica. J Child Neurol 2012; 28: 658-662
25. Elsone L, Townsend T, Mutch K, et al. Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler 2012; 19: 475-479
26. Iones A and Howard J. Hypogeusia as a symptom of neuromyelitis optica spectrum disorder. Mult Scler 2013; 19: 1548-1549
27. Tenembaum S, Pittock S, Princich J, Lennon V and Segura M. Clinical and MR features of paediatric aquaporin-4-IgG seropositive NMOSD 2012 28th Congress of the European Comittee for Research and Treatment in Multiple Sclerosis (ECTRIMS), 2012
28. Kinoshita M and Nakatsuji Y. Where do AQP4 antibodies fit in the pathogenesis of NMO? Mult Scler Int 2012; 2012: 1-6
29. Papeix C, Vidal J-S, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007; 13: 256-259 (Pubitemid 46592781)
30. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239-245
31. Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012; 79: 1065-1066
32. Min J-H, Kim BJ and Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18: 113-115.